Dannex Limited agreed to acquire remaining unknown minority stake in Starwin Products Company Limited/Ayrton Drug Manufacturing Ltd on December 19, 2018. Dannex shareholders will own approximately 55.95%, Ayrton shareholders will own approximately 37.45% and Starwin shareholders will own approximately 6.61%, of the Starwin Products Company Limited/Ayrton Drug Manufacturing Ltd. The transaction is subject to court approval, approval of shareholders of Starwin Products Company Limited and Ayrton Drug Manufacturing Ltd. The transaction is approved by regulatory authorities, Board of Directors of Starwin Products Company Limited/Ayrton Drug Manufacturing Ltd and Dannex Limited. Extraordinary general meeting of shareholders of Starwin Products Company Limited/Ayrton Drug Manufacturing Ltd will be held on December 27, 2018. On December 27, 2018, the transaction is approved by shareholders of Starwin Products Company Limited/Ayrton Drug Manufacturing Ltd and Dannex Limited. On November 25, 2019, the transaction is approved by High Court of Justice. Upon completion, Starwin Products Company Limited/Ayrton Drug Manufacturing Ltd will be renamed to Dannex Ayrton Starwin Limited. UMB investment holdings limited acted as financial advisor, UMB stockbrokers acted as sponsoring broker, Kimathi and Partners acted as legal advisor and Ernst & Young acted as reporting accountant in the transaction. KPMG acted as auditor for Starwin Products Company Limited and Dannex Limited and Ernst & Young - Ghana acted as auditor for Ayrton Drug Manufacturing Ltd. PricewaterhouseCoopers (Ghana) Limited acted as valuer in the transaction. The transaction is expected to be completed on February 12, 2019.